Clinical Trial Finder

Key

Inclusion Criteria:

1. Histologically or cytologically documented disease as follows: 1. Part 1: unresectable, locally advanced or metastatic nonhematologic malignancy that is relapsed/refractory to or intolerant of established therapies known to provide clinical benefit. 2. Part 2: locally advanced or metastatic, low (grade 1) or intermediate (grade 2) grade NETs that have been previously treated with at least 1 line of systemic therapy. 2. Has radiologic evidence of progressive tumour within 12 months of study enrolment. 3. Is willing and able to provide informed consent. 4. Is ≥20 years of age. 5. Has measurable lesions according to RECIST Version 1.1. 6. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 7. Female patients of childbearing potential and male patients with partners of childbearing potential agree to use a highly effective form(s) of contraception.Key

Exclusion Criteria:

1. Women who are pregnant and lactating, or possibly pregnant. 2. Has a history of interstitial lung disease (ILD)/noninfectious pneumonitis, has current ILD/pneumonitis, or has suspected ILD/pneumonitis that cannot be ruled out by imaging at screening. 3. Known active viral hepatits. 4. Has an AE due to previous anti-tumour therapy that has not recovered to ≤CTCAE Grade 1, except alopecia and peripheral neurotoxicity with ≤CTCAE Grade 2 caused by platinum chemotherapy. 5. Uncontrollable hypertension, defined as systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg, despite antihypertensive medication. 6. Gastrointestinal disease or condition within 6 months prior to first dose. 7. Has a history or presence of a serious haemorrhage (>30 mL within 3 months) or haemoptysis (>5 mL blood within 4 weeks) 8. Clinically significant cardiovascular disease. 9. Brain metastases and/or spinal cord compression untreated with surgery and/or radiotherapy, and without clinical imaging evidence of stable disease (SD) for 14 days or longer; patients requiring steroids within 4 weeks prior to start of study treatment will be excluded. 10. A high risk of bleeding at screening due to tumour invasion into major vessels, such as pulmonary artery, the superior vena cava, or the inferior vena cava, as determined by investigators. 11. Has arterial thrombosis or deep venous thrombosis within 6 months prior to first dosing, or thromboembolic events (including stroke and/or transient ischaemic attack) within 12 months prior to first dosing.

The purpose of this study is to evaluate the tolerability and efficacy of surufatinib in Japanese patients. The study will be conducted in 2 parts:

• - Part 1 - evaluation of tolerability and safety of surufatinib and confirmation of the recommended clinical dose in Japanese patients with nonhematologic malignancies.

• - Part 2 - evaluation of antitumor activity and confirmation of tolerability of surufatinib in Japanese patients with NETs.

All patients will be treated with oral surufatinib 300 mg QD in treatment cycles of 28 days starting on Cycle 1 Day 1.

Arms

Experimental: Surufatinib

Oral surufatinib 300 mg once daily in treatment cycles of 28 days starting at Cycle 1 Day1

Interventions

Drug: - Surufatinib

Surufatinib 300 mg oral once daily